- Record: found
- Abstract: found
- Article: not found
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.
Patrick Marcellin
1 ,
George K K Lau ,
Ferruccio Bonino ,
Patrizia Farci ,
Stephanos Hadziyannis ,
Rui Jin ,
Zhi-Meng Lu ,
Teerha Piratvisuth ,
Georgios Germanidis ,
Cihan Yurdaydin ,
Moises Diago ,
Selim Gurel ,
Ming-Yang Lai ,
Peter Button ,
Nigel Pluck
Sep 16 2004
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Available treatments for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term safety implications.